Cutera Aesthetic Device Footprint: FDA Clearances, Warning Letters, and MAUDE Context

What does the public regulatory data reveal about Cutera and its aesthetic device portfolio, and what should a buyer, medical director, clinical operator, or regulatory affairs team do with it?

Analysis of the FDA medical device databases reveals that Cutera holds a focused regulatory footprint in energy-based aesthetic systems. This dossier aggregates and analyzes 20 FDA 510(k) clearances—all registered under the surgical laser product code GEX—alongside its compliance history (specifically its 2022 Warning Letter and resolution) and 122 adverse event reports in the FDA's Manufacturer and User Facility Device Experience (MAUDE) database.

For clinical buyers and practice managers, this data highlights Cutera’s technology evolution (culminating in the 1726nm sebaceous-targeting AviClear), examines its post-market safety records (zero recalls in our registry slice but notable MAUDE event clusters for LimeLight and Titan), and provides a transparent assessment of its regulatory compliance history.

---

1. Corporate History, Technical Focus, and the Shift to Acne Therapeutics

Founded in 1998 in Brisbane, California, by former Coherent laser engineers David Gollnick and John Flower, Cutera, Inc. (initially known as Altus Medical) was established to develop advanced energy-based systems for dermatology and plastic surgery. The company's corporate history is marked by a focus on solid-state laser engineering and a strategic shift from general cosmetic workstations to specialized medical therapeutics:

• Pioneering Altus Era (1998–2002): The company launched Altus CoolGlide, one of the first long-pulse 1064nm Nd:YAG lasers cleared for hair removal in all skin types.
• Rebranding and the xeo Workstation (2003): Rebranded as Cutera in 2003, the company launched the xeo multi-application console. This modular platform combined Nd:YAG lasers with Intense Pulsed Light (IPL) handpieces, allowing clinics to customize their technology offerings.
• The Excel V Vascular Milestone (2011): Cutera introduced the Excel V system, integrating dual solid-state wavelengths: a high-power 532nm green laser (KTP) and a 1064nm Nd:YAG. This combination challenged the dominance of pulsed dye lasers in vascular treatments.
• Acquisition of Juliet Laser (2017): Cutera acquired the distribution rights for the Juliet Erbium:YAG laser from Asclepion Laser Technologies to enter the gynecological and vaginal rejuvenation markets.
• The AviClear Acne Revolution (2022): In March 2022, Cutera received FDA clearance for AviClear, the first 1726nm laser cleared for the treatment of mild, moderate, and severe inflammatory acne. This marked a strategic pivot from cosmetic rejuvenation to medical therapeutics.

These corporate milestones consolidated a focused regulatory footprint, making Cutera a major engineering-driven player in the energy-based device market.

---

2. Cutera's 510(k) Clearance Map

Dermatology and plastic surgery devices are regulated by the FDA as Class II medical devices, requiring a 510(k) premarket notification clearance before commercial distribution. The manufacturer must demonstrate that the device is "substantially equivalent" in safety and efficacy to a legally marketed predicate device.

Analysis of Product Codes

A search of the FDA Medical Device 510(k) Database shows that Cutera holds 20 clearances in our database slice, all registered under a single primary product code:

1. GEX (Laser instrument, surgical): With 20 clearances, this code covers Cutera's entire solid-state laser portfolio, including the CoolGlide, xeo, Excel V, truPulse, enlighten, and AviClear platforms.

Selected Cutera FDA 510(k) Clearances

To illustrate Cutera's regulatory timeline, the following table lists representative clearances spanning their primary technology pillars:

---

3. Core Platforms: Technical Mechanics and Laser Physics

Cutera’s market footprint and clinical reputation are built on four core platforms:

Excel V & Excel V+: Vascular Workstations

Excel V is a leading vascular platform that targets blood vessels in rosacea, telangiectasias, cherry angiomas, port-wine stains, and leg veins. For a head-to-head comparison of how the Excel V KTP platform stacks up against the Candela Vbeam pulsed dye laser for vascular redness, see our Vbeam vs Excel V comparison.

• Dual Wavelengths: It integrates a 532nm KTP laser (highly absorbed by oxyhemoglobin, ideal for superficial facial redness) and a 1064nm Nd:YAG laser (penetrates deeper to target blue/purple leg veins and venous lakes).
• Sapphire Contact Cooling Physics: Sapphire has a very high thermal conductivity, allowing it to act as a heat sink. The cooling window maintains continuous contact with the skin before, during, and after the laser pulse. The operator can set the cooling temperature from 5°C to 20°C depending on the fluence and skin type. This contact cooling prevents the epidermis from overheating while allowing high fluences to target the blood vessels in the dermis.
• Spot Size and Pulse Duration Relations: Spot sizes range from 2mm (for fine telangiectasias) to 16mm (for large vascular malformations). Pulse widths are adjustable from 0.1 ms (for tiny superficial capillaries) to 100 ms (for slow volumetric heating of deep vessels).

xeo: Multi-Application Console

The xeo platform is Cutera's modular workstation, supporting multiple handpieces:

• Laser Genesis (Microsecond Nd:YAG): Unlike traditional long-pulse Nd:YAG lasers that target hair follicles, Laser Genesis delivers energy in microsecond pulses (0.3 ms) at high repetition rates (10 Hz). This rapid pulsing heats the papillary dermis to a target temperature range of 39°C to 42°C. The cumulative thermal energy stimulates neocollagenesis and coagulates micro-capillaries, improving skin texture and resolving diffuse redness without downtime.
• LimeLight (Intense Pulsed Light): The LimeLight handpiece is highly customizable. It features three pre-programmed light spectra (Program A: 520–1100nm, Program B: 560–1100nm, Program C: 580–1100nm) designed to target melanin and hemoglobin at different skin depths, allowing operators to match the program to the patient's skin type and lesion color.
• Titan (Infrared Skin Tightening): Titan uses a broad-spectrum infrared light source (1100nm to 1800nm) to heat the deep dermis (1.0mm to 3.0mm) to a target temperature of 55°C to 65°C. This induces immediate contraction of collagen fibers and initiates long-term dermal remodeling.

enlighten: Pico/Nano Tattoo and Pigment Platform

Developed under K140727, enlighten is a versatile picosecond and nanosecond workstation:

• Dual Pulse Durations (750ps and 2ns): Large ink particles are shattered effectively using nanosecond pulses (2ns) because they require longer thermal relaxation times. As the ink particles fragment into smaller pieces, picosecond pulses (750ps) are utilized to shatter the remaining fine particles. This combination speeds tattoo clearance.
• Three Wavelengths: Wavelengths of 532nm (red/orange inks), 1064nm (dark inks/dark skin), and 670nm (green/blue inks) provide coverage for multi-colored tattoos.

AviClear: 1726nm Acne Therapeutic Laser

Cleared under K213461, AviClear is a specialized laser cleared for the treatment of inflammatory acne. For a deeper clinical look at the 1726nm sebaceous-targeting mechanism and the AviClear acne-clearance trial evidence, see our AviClear 1726nm laser evidence guide.

• Wavelength Selection (1726nm): The 1726nm wavelength is absorbed by lipids (sebum). The energy targets sebaceous glands, heating and down-regulating them to reduce sebum production.
• AviCool Contact Cooling: An integrated sapphire contact cooling system maintains the skin surface temperature at approximately 20°C, preventing epidermal burns while allowing the laser to target the sebaceous glands in the dermis.

---

4. Clinical Protocols and Parameters

Clinical success with Cutera systems relies on adjusting parameters—wavelength, pulse duration, fluence, spot size, and cooling variables—to the patient's skin type and indication.

The following clinical settings matrix outlines representative parameters for Cutera platforms:

Excel V (Vascular Rosacea Protocol Notes)

• Wavelength: 532nm KTP.
• Spot Size: 8mm to 10mm.
• Fluence: 6.5–8.0 J/cm².
• Pulse Width: 10 ms to 15 ms. Long pulse widths heat the vessel slowly, causing coagulation without rupturing the vessel wall, which avoids bruising.
• Sapphire Cooling Temperature: Set to 5°C to 10°C to protect the epidermis from thermal injury.

Laser Genesis (Skin Toning Protocol Notes)

• Wavelength: 1064nm Nd:YAG.
• Pulse Width: 0.3 ms.
• Fluence: 12–15 J/cm².
• Repetition Rate: 10 Hz (10 pulses per second).
• Clinical Endpoint: The treatment is delivered by moving the handpiece continuously over the skin until a target temperature of 39°C to 42°C is reached, maintained for 3 to 5 minutes per zone. This stimulates collagen synthesis and resolves diffuse redness.

AviClear (Acne Treatment Protocol Notes)

• Wavelength: 1726nm.
• Treatment Grid: The handpiece is placed in overlapping stamp passes across the face.
• Cooling Calibration: The system calibrates the AviCool sensor before firing. The laser will not fire if the cooling contact is unstable, protecting the epidermis.
• Treatment Course: Three 30-minute sessions spaced 4 weeks apart.

---

5. Sebaceous Gland Photothermolysis

The clinical mechanism of AviClear is based on selective photothermolysis of sebaceous glands.

  SEBACEOUS GLAND TARGETING MECHANISM (1726nm)
  ┌────────────────────────────────────────────────────────┐
  │ Wavelength: 1726nm                                     │
  │ Target Chromophore: Lipids (Sebum)                     │
  │ Absorption Ratio: 1726nm absorption in fat is roughly │
  │                   2x higher than in water.             │
  │                                                        │
  │ Dermal Heating Profile:                                │
  │    * Laser energy penetrates to 1.0mm - 2.0mm depth.   │
  │    * Epidermis protected by AviCool contact cooling.   │
  │    * Energy heats and damages sebaceous glands.        │
  │    * Sebum production decreases, resolving acne.       │
  └────────────────────────────────────────────────────────┘

Lipids vs. Water Absorption

• The 1720nm Spectral Window: In tissue optics, water is the dominant chromophore. However, near 1726nm, there is a local absorption peak where the absorption coefficient of lipids (fat/sebum) exceeds that of water by a factor of two.
• Thermal Injury Zone: The sebaceous glands lie in the dermis at a depth of 1.0mm to 2.0mm. Delivering 1726nm laser energy heated by lipids selectively raises the temperature of the sebaceous gland, inducing thermal damage that down-regulates sebum production.
• Comparison to Isotretinoin: Like oral isotretinoin, AviClear down-regulates sebaceous gland activity, but achieves this via selective photothermolysis without the systemic side effects (teratogenicity, dry skin, liver toxicity) of oral medication.

---

6. FDA Warning Letters & Regulatory Incidents: The Juliet Case

Analyzing a company's regulatory history is essential for assessing compliance and operational risk. Unlike manufacturers with systemic warning letters, Cutera's regulatory record is dominated by a single compliance event: the November 10, 2022 Warning Letter (CMS #639552).

Summary of the Warning Letter (Juliet Laser System)

• The Device: The Juliet; MCL 31 Dermablate System is a 2940nm Er:YAG laser system manufactured by Asclepion and distributed by Cutera. It was cleared for skin resurfacing and general surgery.
• The Issue: The FDA determined that Cutera was promoting the Juliet system for gynecological indications—specifically "vaginal rejuvenation," treating vulvovaginal atrophy, and urinary incontinence—without obtaining a Premarket Approval (PMA) or a new 510(k) clearance for those uses. The FDA classified the device as adulterated and misbranded.
• Timeline and Regulatory Actions:
  • 2018 (Safety Alerts): The FDA warned the aesthetic industry regarding unapproved laser vaginal treatments, citing risks of vaginal burns and scarring.
  • 2019 (Voluntary remediation): Cutera voluntarily stopped marketing the Juliet laser for vaginal rejuvenation and removed all brochures and promotional videos.
  • 2022 (Warning Letter): During web surveillance, the FDA identified an active, third-party-hosted landing page (MyJuliet) containing marketing claims for unapproved vaginal indications. The FDA issued a formal Warning Letter to Cutera.
  • 2023 (Resolution): Cutera confirmed the website had been deactivated immediately. In communications dated February 8, 2023, and March 9, 2023, the FDA reviewed Cutera's corrective actions. The FDA acknowledged that Cutera had resolved the website oversight and that no further regulatory actions were required.

This incident highlights the need for strict quality controls over third-party digital marketing and web assets.

---

7. Adverse Events: Analysis of the FDA MAUDE Database

The FDA’s MAUDE database compiles reports of medical device malfunctions, injuries, and deaths. It is a critical post-market surveillance tool, though it cannot establish clinical incidence rates due to under-reporting and lack of denominator data (total treatment volumes).

A search of the FDA MAUDE database summary reveals 122 reports associated with Cutera devices:

• Injury Reports: 82
• Malfunction Reports: 18
• Other/Unspecified Reports: 18
• Death Reports: 0 (Cutera’s non-invasive aesthetic portfolio shows zero death reports in the registry).
• Unspecified/NaN: 4

Event Distribution by Brand

1. LimeLight IPL: 15 reports
2. Titan XL: 14 reports
3. Laser Genesis: 14 reports
4. GenesisPlus: 9 reports
5. xeo: 6 reports
6. Titan: 4 reports
7. Excel V: 4 reports
8. AviClear: 4 reports

MAUDE Adverse Event Distribution
Cutera (122 total reports, by manufacturer)
  ├── Injury: 82 (67.2%)
  ├── Malfunction: 18 (14.8%)
  ├── Other: 18 (14.8%)
  └── Unspecified: 4 (3.2%)

Key Clinical Safety Analysis

LimeLight IPL (Pigment and Redness)

Adverse events are dominated by localized thermal injuries and pigmentary changes:

• Thermal Burns and Striping: Burns occur when the operator uses excessive fluence, selects an incorrect skin program, or fails to maintain flat contact between the sapphire window and the skin. In IPL treatments, poor contact can cause "striping" (rectangular burn marks matching the light guide shape).
• Fitzpatrick Classification Errors: Burn risks are significantly higher when IPL is performed on patients with tanned skin or Fitzpatrick skin types IV–VI, where high epidermal melanin absorbs the light energy, causing burns and post-inflammatory hyperpigmentation (PIH).

Titan (Infrared Skin Tightening)

• Deep Dermal Burns and Blistering: The Titan handpiece uses infrared light to heat the deep dermis. Reports describe burns occurring when the operator delivers overlapping pulses without allowing the tissue to cool, or when the integrated cooling window fails to protect the epidermis.
• Localized Fat Loss (Lipoatrophy): A rare adverse event where excessive deep heating damages subcutaneous fat cells, causing localized hollows.

Laser Genesis (Nd:YAG Toning)

• Transient Erythema and Swelling: Laser Genesis is a gentle treatment. While mild redness and swelling are expected endpoints, patients occasionally report them as adverse events due to inadequate pre-procedure education.

---

8. Cutera Body Contouring Systems: truSculpt iD and truSculpt Flex

In addition to its vascular and acne laser lines, Cutera maintains a major footprint in non-invasive body contouring through its truSculpt platform family, cleared under electrosurgical product codes GEI and NGX:

truSculpt iD: Monopolar Radiofrequency Fat Reduction

truSculpt iD operates at 1 MHz or 2 MHz, delivering monopolar radiofrequency energy. This configuration travels deeply through the skin to target subcutaneous adipose tissue.

• Lipid Heating Profile: The energy heats the subcutaneous fat layer to a target temperature range of 43°C to 45°C while maintaining the overlying epidermis at approximately 39°C to 41°C using continuous contact cooling. Heating fat cells to this temperature range for 15 minutes induces localized fat cell apoptosis. Over the following 8 to 12 weeks, the damaged fat cells are removed by the lymphatic system.
• Hands-Free Multi-Applicator Delivery: truSculpt iD features six hands-free applicators that can be secured to the abdomen and flanks simultaneously. Each applicator measures skin impedance continuously and adjusts its RF energy output to maintain uniform tissue heating, reducing the operator-dependent variability associated with manual handpieces.

truSculpt Flex: Multi-Directional Stimulation (MDS)

truSculpt Flex is a non-invasive muscle stimulation platform cleared under product code NGX (Muscle Stimulator, Class II, 21 CFR 890.5850):

• Multi-Directional Stimulation (MDS) Physics: Unlike older electromagnetic muscle stimulators (such as HIFEM) that stimulate the entire muscle group uniformly, truSculpt Flex delivers direct electrical current to the muscle motor nerves via 16 gel pads placed in pairs across targeted muscle groups. This direct stimulation allows the system to target specific muscle groups with localized muscle contractions.
• Three Biomechanical Treatment Modes:
  1. Prep Mode (Warm-up): Delivers a series of rapid, low-intensity contraction pulses to warm up the muscles, stimulate blood circulation, and prepare the tissue for high-intensity work.
  2. Tone Mode (Endurance): Delivers prolonged muscle contractions to point of fatigue, followed by brief recovery cycles, designed to increase muscle endurance and core strength.
  3. Sculpt Mode (Hypertrophy): Delivers high-intensity, deep muscle contractions designed to micro-tear muscle fibers, stimulating hypertrophy (muscle building) and increasing local metabolic activity.
• Consumable Gel Pads: The platform utilizes proprietary gel pads that ensure stable electrical coupling. Practice managers must track consumable gel pad costs in their clinical ROI calculations.
• Clinical Skin Prep and Electrode Placement: Prior to treatment, the operator must cleanse the patient's skin with alcohol to remove surface oils. Gel pads are applied in pairs across targeted muscle groups (e.g., rectus abdominis, obliques, quadriceps, gluteal muscles) with specific vector alignments to target motor points. The stimulation current is ramped up gradually in milliamperes (mA) to the patient's maximum tolerable muscle contraction threshold, maintaining full contractions throughout the cycle to trigger hypertrophy.

The following table maps the specific parameters and biomechanical targets for the truSculpt Flex modes:

---

9. Clinical Workflows and Treatment Techniques

To maximize efficacy and patient safety, clinical operators must follow structured, evidence-based workflows for Cutera's flagship systems.

Excel V Vascular Workflow: Step-by-Step

Treatment of vascular lesions requires careful parameter setting to ensure photothermolysis occurs without vessel rupture:

1. Skin Preparation: Cleanse the treatment area thoroughly with a non-alcohol-based cleanser. If alcohol is used to sanitize the skin, ensure it has completely evaporated to prevent a fire hazard when the laser is activated. Do not apply topical numbing creams for vascular treatments; anesthetics cause vasoconstriction, making target blood vessels disappear and significantly reducing treatment efficacy.
2. Distance Gauge and Sapphire Placement: Apply a thin layer of clear ultrasound gel to the skin. Press the sapphire cooling window flat against the gel. The contact must be firm and parallel to the skin to ensure the sapphire acts as a heat sink, protecting the epidermis.
3. Wavelength and Spot Selection: Use the 532nm wavelength for superficial red vessels (telangiectasias, rosacea). Use the 1064nm wavelength for deep blue/purple vessels (leg veins, venous lakes). Select a spot size that matches the diameter of the vessel: a 2mm to 4mm spot for isolated telangiectasias, and up to 10mm for diffuse rosacea.
4. Pulse Duration Calibration: Set the pulse width based on the vessel size. Small superficial vessels (diameter < 0.2mm) require shorter pulse widths (e.g., 5 ms to 10 ms). Larger vessels or vascular malformations require longer pulse widths (e.g., 20 ms to 40 ms) to heat the vessel slowly, causing coagulation.
5. Clinical Endpoint Monitoring: Monitor the treated vessel immediately after each pulse. The target endpoint is immediate vessel clearance (disappearance) or vessel spasm (vasoconstriction). If the vessel turns immediate dark purple or if micro-bleeding occurs under the skin, it indicates that the energy was delivered too quickly (the pulse width was too short), causing vessel rupture rather than coagulation. In this case, increase the pulse duration and decrease the fluence slightly.

Laser Genesis Technique: Achieving Therapeutic Thermal Targets

Laser Genesis is a non-ablative, microsecond 1064nm Nd:YAG treatment that relies on cumulative thermal energy to stimulate collagen synthesis:

1. Continuous Motion Technique: The operator must keep the handpiece in constant motion, maintaining a distance of 1 to 2 centimeters from the skin surface. The handpiece is moved in a scanning, hover motion across the treatment zone. Never hold the handpiece stationary, as this will cause localized heat spikes and epidermal burns.
2. Target Temperature Monitoring: Use an infrared thermometer to measure the skin surface temperature continuously. To stimulate neocollagenesis effectively, the skin surface temperature must reach a target range of 39°C to 42°C and be maintained in this zone for 3 to 5 minutes per treatment quadrant (e.g., cheek, forehead).
3. Treatment Endpoints: The patient should feel a pleasant, warm sensation. Clinical endpoints include mild erythema (redness) and slight edema (swelling), which indicate that the papillary dermis has reached the therapeutic thermal threshold.

---

10. Regulatory Compliance and Buying Guide for Practice Managers

For practice managers, medical directors, and laser technicians, purchasing and operating Cutera platforms requires a structured compliance and maintenance framework:

Used Cutera Workstation Purchase Checklist

Due to the high cost of new platforms, many clinics purchase refurbished Cutera workstations. Practice managers should execute this specific quality audit prior to completing a purchase:

Maintenance and Room Safety Controls

Class IV medical lasers require strict safety controls to prevent irreversible ocular damage:

• Nominal Ocular Hazard Distance (NOHD): For Cutera lasers, the NOHD can exceed 100 meters. The laser room door must be closed during treatment, windows must be covered with opaque blocking shields, and warning signs must be posted at all entrances.
• Eye Protection (OD Values): Operators and patients must wear laser safety glasses matching the target wavelength. For the 532nm KTP wavelength, eyewear must have an Optical Density (OD) of 6 or higher. For the 1064nm Nd:YAG wavelength, the OD must be 6 or higher. The specific wavelengths and ODs are printed on the frames.

---

11. FAQs

Is the AviClear laser FDA-cleared?

Yes. The Cutera AviClear laser system is FDA-cleared under product code GEX. It holds clearances for the treatment of mild, moderate, and severe inflammatory acne.

What is the purpose of Cutera's GEX product code?

GEX is the FDA product code for "Laser instrument, surgical" regulated under 21 CFR 878.4810. It is a Class II regulatory classification. Cutera holds 20 clearances under this code, covering their Nd:YAG, KTP, and 1726nm laser systems.

Are there active recalls for Cutera aesthetic devices in 2026?

According to the FDA database, there are no active, open recalls for Cutera aesthetic devices. The company has a clean manufacturing safety profile with zero recalls listed in our database slice.

What was the result of Cutera's 2022 Warning Letter?

The Warning Letter addressed the off-label marketing of the Juliet laser for vaginal rejuvenation on a legacy website. Cutera took down the website and implemented corrective actions, resolving the regulatory issue in early 2023.

What is the function of the AviCool cooling system?

AviCool is Cutera's contact cooling system integrated into the AviClear handpiece. It maintains the skin surface temperature at approximately 20°C during treatment, protecting the epidermis from burns while allowing the 1726nm laser energy to target sebaceous glands.

Can the Excel V laser treat spider veins on the legs?

Yes. The Excel V laser uses a 1064nm Nd:YAG wavelength that penetrates deeply to target and coagulate blue and purple lower-extremity spider veins and reticular veins.

How does the Excel V continuous contact cooling compare to DCD cryogen cooling?

Excel V uses a sapphire contact cooling window that cools the skin continuously before, during, and after the laser pulse. DCD systems spray a cryogen coolant in brief millisecond bursts. Sapphire contact cooling provides stable, continuous temperature control, which is preferred for vascular procedures that require prolonged laser pulses.

What is the difference between Excel V and Excel V+?

The Excel V+ is the updated vascular platform. It features higher peak power, a redesigned dermastat handpiece with adjustable spot sizes up to 16mm, and a pen-like handpiece design that improves visualization during telangiectasia treatments.

Can Laser Genesis be performed on dark skin safety?

Yes. Laser Genesis is highly safe for all Fitzpatrick skin types (I–VI) because it delivers microsecond pulses of 1064nm Nd:YAG laser energy. This wavelength has low melanin absorption, and the rapid pulsing heats the dermis slowly, preventing epidermal burns.

What is the clinical endpoint for Excel V vascular treatments?

The clinical endpoint is vessel clearance (disappearance) or vessel spasm (vasoconstriction). If purpura (bruising) occurs immediately, it indicates that the pulse width was too short, causing vessel rupture rather than coagulation.

What is the difference between truSculpt iD and truSculpt 3D?

truSculpt iD is the latest hands-free platform that uses six synchronized 2 MHz RF applicators to treat multiple body zones (like the abdomen and flanks) simultaneously in a single 15-minute cycle. truSculpt 3D is a legacy platform that relies on a single manual handpiece, requiring the operator to massage each treatment zone sequentially for 15 minutes per zone.

Can Laser Genesis be stacked with other treatments in the same session?

Yes. Laser Genesis is a non-ablative, microsecond treatment that is frequently stacked with chemical peels or IPL treatments. Stacking Laser Genesis before an IPL treatment can improve pigment clearing by stimulating blood circulation and skin metabolism, but it must be performed with conservative energy settings to prevent thermal injury.

What is the clinical role of the Pearl Er:YSGG laser?

The Pearl platform uses a 2790nm erbium-doped yttrium scandium gallium garnet (Er:YSGG) wavelength. This wavelength has a water absorption profile that falls between Er:YAG (2940nm) and CO2 (10600nm). This allows the Pearl laser to provide a combination of superficial ablation (peeling) and deeper thermal heating, treating wrinkles and texturing with shorter downtime than a traditional carbon dioxide laser.

Can truSculpt Flex treat muscle atrophy?

Yes. Under its NGX clearance, truSculpt Flex is cleared for muscle re-education and treating muscle atrophy resulting from disuse, making it useful in rehabilitation and physical therapy programs in addition to aesthetic muscle toning.

Is truSculpt iD cleared by the FDA?

Yes. truSculpt iD is FDA-cleared under product code GEI as an electrosurgical device. It is indicated for non-invasive lipolysis (fat reduction) of the abdomen and flanks, as well as the submental area.

What is the difference between truSculpt iD and cryolipolysis (fat freezing)?

truSculpt iD uses monopolar radiofrequency energy to heat fat cells to induce apoptosis, while cryolipolysis (e.g., CoolSculpting) freezes fat cells. truSculpt iD has the added benefit of heating the dermis to stimulate skin tightening, and its hyperthermic mechanism does not carry the risk of Paradoxical Adipose Hyperplasia (PAH) associated with freezing procedures.

Is truSculpt Flex cleared by the FDA and under what code?

Yes. truSculpt Flex is FDA-cleared under product code NGX as a muscle stimulator. It is indicated for muscle strengthening, toning, and firming of the abdomen, buttocks, and thighs.

What are the main contraindications for truSculpt Flex treatments?

truSculpt Flex is contraindicated for patients with cardiac pacemakers, implanted defibrillators, or other active implanted electronic devices. It is also contraindicated over active skin infections, open wounds, or abdominal hernias, and is not recommended during pregnancy or lactation.

Can the Excel V laser treat birthmarks such as port-wine stains?

Yes. The 532nm KTP and 1064nm Nd:YAG wavelengths target oxyhemoglobin in blood vessels. Excel V is cleared and clinically proven for the treatment of capillary vascular malformations, including pediatric and adult port-wine stains.

What is the clinical significance of truSculpt Flex's MDS technology?

Multi-Directional Stimulation (MDS) allows the system to target motor nerves directly via electrical currents, generating deep muscle contractions that mimic various exercise patterns (twisting, holding, rapid contraction) to stimulate hypertrophy and build strength.

How many treatment sessions are typically required for truSculpt iD?

A typical truSculpt iD treatment requires a single 15-minute hands-free session per zone, achieving up to 24% fat layer thickness reduction on average at 12 weeks. Some patients select a second session for additional contouring.

Are there any contraindications for Laser Genesis treatments?

Laser Genesis has very few contraindications since it is a non-ablative, microsecond treatment. However, it should not be performed over active skin infections, open wounds, or in patients taking highly photosensitizing medications.

---

Sources

1. FDA 510(k) Premarket Notification Database: FDA 510(k) Search Tool (Referencing clearances K251149 and K213461 for AviClear, K233237 for Excel V+, and K050047 for Titan).
2. FDA Warning Letters Database: FDA Warning Letter CMS #639552 (Official Warning Letter issued to Cutera, Inc. regarding the Juliet; MCL 31 Dermablate System, dated November 10, 2022, and subsequent close-out records).
3. FDA Manufacturer and User Facility Device Experience (MAUDE) Database: FDA MAUDE Search Tool (Extracted and aggregated data for Cutera devices).
4. Cutera Corporate and Clinical Publications: Cutera Medical Systems (Prescribing information, clinical guidelines, and AviCool cooling specifications).